ALDX Faces Securities Class Action Investigation Amid FDA Setback—What Should Investors Watch Now?

Legal Action Launches After FDA Rejection—and ALDX Stock Reaction Is Sharp

Shareholders in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) are navigating an uncertain landscape after two major events shook the company. First, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for reproxalap, Aldeyra’s lead drug candidate for dry eye disease, citing inadequate and inconsistent clinical evidence. Now, the Rosen Law Firm has announced a securities class action investigation, raising fresh concerns for investors.

What Triggered the Investigation? Key Details from the Press Release

According to the March 21, 2026 press release, the Rosen Law Firm is investigating potential securities claims following allegations that Aldeyra may have issued "materially misleading business information" to investors. The trigger: Aldeyra’s March 17 SEC filing disclosed the receipt of an FDA CRL, which bluntly stated there was a “lack of substantial evidence” that reproxalap works as claimed, and that trial results were inconsistent and unreliable. This drove ALDX shares to fall as much as 70.7% in a single session, bottoming at $1.24 on March 17.

Today’s Market Snapshot: Stock Bounces but Legal Uncertainty Lingers

As of 11:43 AM, ALDX is trading at $2.24, recovering some of its losses but still well below its pre-CRL levels. The stock is up 23.76% intraday, showing volatility as news digests. Here’s a look at notable figures:

The Bigger Picture: What Could This Mean for ALDX Investors?

The combination of a failed regulatory milestone and the launch of a securities class action investigation introduces added risk and uncertainty for Aldeyra shareholders. Historically, securities actions tied to FDA rejections can linger for months or years, dampening investor confidence and raising the likelihood of further volatility. While the Rosen Law Firm has a track record of winning settlements, no outcome is guaranteed.

Investors should note that the FDA's criticism is rooted in fundamental doubts about the drug’s effectiveness, not just procedural technicalities. The legal inquiry will likely probe whether Aldeyra adequately disclosed the risks or mischaracterized the clinical results in communications to the public and investors both prior to and during the drug application process.

Key Takeaway: Know the Risks—and Next Steps

With shares staging a partial rebound but no immediate resolution in sight, ALDX faces an unpredictable path. Any potential recovery will depend on the outcome of legal proceedings, Aldeyra’s strategic pivot, and potential future regulatory developments. Investors may want to monitor further company disclosures, FDA interactions, and case updates from the Rosen Law Firm.

For those considering involvement or seeking compensation, the press release provides resources to join the prospective class action. In the meantime, heightened volatility and legal scrutiny will likely keep ALDX stock in focus among risk-tolerant investors.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI